TC BIOPHARM (HOLDINGS) PLC |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.61 USD | -6.94% |
|
-9.55% | -49.21% |
| Sales 2022 | 3.84M 4.8M | Sales 2023 | - | Capitalization | 1.35M 1.69M |
|---|---|---|---|---|---|
| Net income 2022 | -1M -1.25M | Net income 2023 | -5M -6.24M | EV / Sales 2022 | 0.26 x |
| Net cash position 2022 | 2.01M 2.51M | Net cash position 2023 | 661K 825K | EV / Sales 2023 | - |
| P/E ratio 2022 |
-1.57
x | P/E ratio 2023 |
-0.13
x | Employees | 41 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 74.24% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
| 1 day | -6.94% | ||
| 1 week | -15.26% | ||
| Current month | +22.90% | ||
| 1 month | -16.15% | ||
| 3 months | -36.86% | ||
| 6 months | -78.34% | ||
| Current year | -49.21% |
1 week
1.60
1.98
1 month
1.183.27
Current year
0.853.35
1 year
0.8538.00
3 years
0.853 500.00
5 years
0.853 500.00
10 years
0.853 500.00
| Managers | Title | Age | Since |
|---|---|---|---|
Michael Leek
FOU | Founder | 64 | 12-12-31 |
Bryan Kobel
CEO | Chief Executive Officer | 44 | 21-05-31 |
Martin Thorp
DFI | Director of Finance/CFO | 72 | 14-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Mark Bonyhadi
BRD | Director/Board Member | 70 | 22-02-21 |
Martin Thorp
DFI | Director of Finance/CFO | 72 | 14-12-31 |
Arlene Morris
CHM | Chairman | 72 | 22-02-21 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-15 | 1.31 | -18.63% | 370,249 |
| 24-04-12 | 1.61 | -6.94% | 155,151 |
| 24-04-11 | 1.73 | +1.76% | 108,462 |
| 24-04-10 | 1.7 | -8.60% | 318,734 |
| 24-04-09 | 1.86 | +4.49% | 441,003 |
End-of-day quote Nasdaq, April 11, 2024
More quotes
TC BioPharm Limited is a clinical-stage biopharmaceutical company. The Company is engaged in developing advanced allogeneic CAR-T cell therapy products for the treatment of cancer, as well as developing gamma-delta T cell therapies for the treatment of infectious disease. The Company's platform technology allows the Company to design specific therapies to treat a range of cancers and infectious diseases with off-the-shelf allogeneic gamma-delta T cell (GDT) products. The Company's pipeline includes OmnImmune and CAR-T programs. OmnImmune is an unmodified allogeneic gamma-delta T cell product being used for the treatment of acute myeloid leukemia (AML). The Company has completed a Phase II clinical trial. Its CAR-T programs include in-house and partner programs at the pre-clinical-stage focused on developing CAR modified allogeneic gamma delta T-cell products targeting solid and hematological indications.
| 1st Jan change | Capi. | |
|---|---|---|
| -49.21% | 5.14M | |
| +1.23% | 42.63B | |
| +51.65% | 42.32B | |
| +5.72% | 40.26B | |
| -9.58% | 27.27B | |
| +8.10% | 25.24B | |
| -22.42% | 18.78B | |
| +2.09% | 12.39B | |
| +28.86% | 12.24B | |
| +5.78% | 10.95B |
- Stock Market
- Equities
- TCBP Stock
